Bayer Advances Nurandociguat Safety Study in Coronary Artery Disease: What Investors Should Watch
Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bayer (BAYRY) is preparing a Phase 1 trial called “A Randomized, Placebo-controlled, Single Blind Drug-drug Interaction Study” in stable coronary artery disease. The goal is to see how safe nitroglycerin is and how it affects the body when taken with the new drug nurandociguat, which could matter for patients who often have both heart and kidney problems.
The study tests a fixed dose of nitroglycerin spray together with either nurandociguat tablets or a look‑alike placebo tablet. Both drugs relax blood vessels, so researchers want to check if using them together causes extra drops in blood pressure or other side effects that could limit future use.
The trial is interventional and randomized, meaning participants are assigned by chance to active drug or placebo. It uses a parallel design with most people, their doctors, and outcome assessors kept blinded, so only key Bayer staff can see who is on which treatment to monitor safety in real time.
The study is listed as not yet recruiting, with first submission on 2026-02-16 and the latest update on 2026-02-23. These early regulatory dates show the program is still in setup and signals Bayer’s intent to move nurandociguat forward while building a safety case for real‑world use with common heart medicines.
For investors, the update is a small but positive sign that Bayer is investing in cardiorenal innovation where long‑term demand is strong. If nurandociguat proves safe with nitroglycerin, it could support broader adoption and strengthen Bayer’s position versus other heart and kidney drug makers, though any earnings impact remains years away.
The study remains in planning with status “not yet recruiting,” and further details are available and updated on the ClinicalTrials.gov portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.
